Long-Term Follow-Up of Subjects in a Phase 1, 2, or 3 Clinical Trial in Which Boceprevir or Narlaprevir Was Administered for the Treatment of Chronic Hepatitis C
Phase of Trial: Phase II/III
Latest Information Update: 19 Sep 2018
At a glance
- Drugs Boceprevir (Primary) ; Narlaprevir
- Indications Hepatitis C
- Focus Adverse reactions; Therapeutic Use
- Sponsors Merck Sharp & Dohme
- 31 Aug 2018 Biomarkers information updated
- 17 Nov 2014 Status changed from completed to discontinued according to ClinicalTrials.gov record.
- 20 Oct 2014 Trial status changed from active, no longer recruiting to completed, according to ClinicalTrials.gov record.